
Sign up to save your podcasts
Or


In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4.1
1212 ratings
In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.

3,217 Listeners

1,720 Listeners

4,345 Listeners

2,201 Listeners

406 Listeners

1,967 Listeners

353 Listeners

1,657 Listeners

145 Listeners

96 Listeners

3,976 Listeners

1,425 Listeners

337 Listeners

34 Listeners

170 Listeners